10:47 AM EDT, 07/24/2026 (MT Newswires) -- Roche Holding (RO.SW) received a 510(k) clearance from the US Food and Drug Administration for its molecular diagnostic test cobas, according to a Friday release. The Swiss drugmaker's cobas test detects Bacterial vaginosis and Candida vaginitis from a single vaginal swab sample and is intended for professional laboratory use.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.